Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP.
Verstovsek S, et al. Among authors: tam cs.
Leuk Res. 2014 Mar;38(3):316-22. doi: 10.1016/j.leukres.2013.12.006. Epub 2013 Dec 11.
Leuk Res. 2014.
PMID: 24374145
Free PMC article.
Clinical Trial.